Henry M. Jackson Foundation for the Advancement of Military Medicine
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
The goal of the Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) study is to conduct, on a yearly basis, direct comparisons of immunogenicity and reactogenicity of the most recent versions of FDA-approved vaccines for COVID-19 and/or influenza. Studies will be conducted on individuals that are FDA eligible to receive these vaccines and do not have a medical condition that severely impairs their immune system. For 2026, the study will directly compare the immunogenicity and reactogenicity of the 2026 Novavax recombinant COVID-19 vaccine with the 2026 Pfizer/BioNTech mRNA COVID-1…
Inclusion Criteria 1. 18-79 years old 2. Have a history of any of the following risk factors for severe COVID: Current: * Age \> 65 years old * Physical inactivity (defined as \<150 mins of moderate activity per week or \<75 mins of vigorous activity per week) * HIV with CD4 count ≥ 500 cells/ul * Smoker * Obesity with BMI ≥ 30 and \< 40 History of: * Asthma * Depression or other mood disorder * Schizophrenia spectrum disorder * Cerebrovascular disease * Heart failure * Coronary artery disease * Cardiomyopathy * Pulmonary embolism * Pulmonary…
COVID-19 Vaccine, mRNA
Recombinant protein vaccine
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.